Immune-modulatory and regenerative properties of MSCs and reports on treatment of GvHD in the literature encouraged us to administer third-party MSCs (1.98 × 106 CD73+/CD105+ cells/kg of recipient weight, obtained from an unrelated male donor). This evidence concerns the gene NT5E and graft versus host disease.